Table 1.

Baseline patients’ characteristics

Baseline characteristics
Characteristics	Olaparib and durvalumab (n=35)*
Age, years, median (range)	63 (40-85)
ECOG performance status, 0/1/2	9 (26%) / 25 (71%) / 1 (3%)
Tumor type
Ovarian carcinoma/Primary peritoneal carcinoma	34 (98%)/ 1 (2%)
Platinum-sensitive / Platinum-resistant**	5 (14 %)/ 30 (86%)
High grade serous / Endometrioid / Mucinous	31 (88%) / 3 (9%) / 1 (3%)
BRCA mutation status
Germline / somatic / wild-type	6 (17%)/ 2 (6%) / 27 (77%)
Lines of prior therapy
1	4 (11%)
2-3	13 (37%)
≥ 4	18 (52%)
Prior PARP inhibitor	2 (6%)
Prior bevacizumab	16 (46%)

^*36 patients were enrolled. One patient was found to have brain metastases three days after her first durvalumab infusion and olaparib. At baseline, she had no symptoms or signs suggestive of brain metastasis but brain MRI due to new onset of dizziness confirmed metastases. She was thus taken off treatment for being ineligible and also for intercurrent illness, thus was not evaluable for outcome.

^**Patients were categorized as platinum-sensitive (progression ≥ 6 months after last platinum-based therapy) or platinum-resistant (progressed <6 months after last platinum-based therapy).

Abbreviations: ECOG = Eastern Cooperative Oncology Group; PARP = poly (ADP-ribose) polymerase.